Independent research on the U.S. markets, Baptista Research

Baptista Research

Independent research on the U.S. markets

Baptista Research is an independent financial research house focused on the U.S. markets. We provide equity research as well as credit research reports on the top-listed U.S. companies with most of our focus on technology, consumer goods and services, automobiles, industrials, oil and gas, pharma, and healthcare. Our research has served more than 3000 institutional investors including mutual funds, hedge funds, banks, family offices, and various buy-side firms. We operate a research subscription service where institutions, as well as retail investors, can have priority access to all our research. We also have a wide distribution of our research reports across some of the top global financial platforms. Apart from equity research and credit research, we also provide advisory services with respect to mergers & acquisitions (M&A), private equity/ venture capital fundraising, valuation reports, and investment management services for corporates.
Baptista Research is owned and managed by Ishan Majumdar, an ex-Venture Capitalist/ Investment Banker, a Chartered Accountant, and a Masters’ degree holder in Management from HEC Paris. Ishan has nearly a decade of experience in Mergers and Acquisitions, Leveraged Buyouts (LBOs), Venture Capital Investing, Corporate Strategy, and Valuation in front-office roles at the likes of BNP Paribas CIB, Credit Agricole CIB, Groupe Danone, and TIW Private Equity. He has worked on and closed multiple acquisition deals, leveraged buyouts, and start-up investment transactions.

Equity Bottom-Up

<ul><li>The recent earnings call for Pfizer provides a detailed look at the company's financial and operational performance in the third quarter of 2025.</li><li>The discussion reveals several pivotal aspects of Pfizer's current business strategy and future outlook.</li><li>Financially, Pfizer reported revenues of $16.7 billion, marking a 7% operational decline from the same period last year, primarily due to reduced contributions from COVID-19 products like Paxlovid and Comirnaty.</li></ul>

The recent earnings call for Pfizer provides a detailed look at the company's financial and operational performance in the third quarter of 2025.The discussion reveals several pivotal aspects of Pfizer's current business strategy and future outlook.Financially, Pfizer reported revenues of $16.7 billion, marking a 7% operational decline from the same period last year, primarily due to reduced contributions from COVID-19 products like Paxlovid and Comirnaty.

Pfizer Secures a Major Regulatory Win—How Will Its U.S. Drug Pricing Deal Shape 2026?

Podcast of business and financial stories, Behind the Money

Behind the Money

Podcast of business and financial stories

From hostile takeovers to C-suite intrigue, Behind the Money takes you inside the business and financial stories of the moment with reporting from Financial Times journalists around the world.

<ul>
<li>Pfizer and Novo Nordisk engaged in a heated battle for control over biotech company Metcera, which is developing innovative weight loss drugs</li>
<li>Novo Nordisk, once seen as a leader in the obesity drug market, has recently faced challenges and a decline in stock price due to competition from Eli Lilly and a weaker drug pipeline</li>
<li>Investors are closely watching the outcome of the bidding war between Pfizer and Novo Nordisk, as the future of the weight loss drug market could be lucrative and competitive</li>
</ul>
<p><em>This content is sourced through publicly available sources and has been machine generated. Information displayed is for general informational purposes only.</em></p>


Pfizer and Novo Nordisk engaged in a heated battle for control over biotech company Metcera, which is developing innovative weight loss drugs
Novo Nordisk, once seen as a leader in the obesity drug market, has recently faced challenges and a decline in stock price due to competition from Eli Lilly and a weaker drug pipeline
Investors are closely watching the outcome of the bidding war between Pfizer and Novo Nordisk, as the future of the weight loss drug market could be lucrative and competitive

This content is sourced through publicly available sources and has been machine generated. Information displayed is for general informational purposes only.

Pfizer and Novo Nordisk’s $10bn battle over weight-loss drugs

<ul><li>Pfizer Inc has announced a definitive agreement to acquire clinical-stage biopharmaceutical company Metsera Inc. for $47.50 per share in cash, a 42.5% premium to Metsera's last closing price, with an additional $22.50 per share potentially payable through contingent value rights (CVRs) linked to key clinical milestones.</li><li>The total deal value could reach $7.3 billion.</li><li>This strategic move follows Pfizer's earlier struggles in the obesity segment after the failure of its weight-loss pill and declining COVID-19 revenues.</li></ul>

Pfizer Inc has announced a definitive agreement to acquire clinical-stage biopharmaceutical company Metsera Inc. for $47.50 per share in cash, a 42.5% premium to Metsera's last closing price, with an additional $22.50 per share potentially payable through contingent value rights (CVRs) linked to key clinical milestones.The total deal value could reach $7.3 billion.This strategic move follows Pfizer's earlier struggles in the obesity segment after the failure of its weight-loss pill and declining COVID-19 revenues.

Pfizer's $4.9 Billion Metsera Bet: Can It Threaten Novo & Lilly’s Obesity Dominance?

<ul><li>Pfizer's Q2 2025 financial results reflect a blend of strategic execution and a challenging external milieu.</li><li>The company reported revenues of $14.7 billion, marking a 10% operational increase year-over-year, driven by robust growth across the U.S. and international divisions.</li><li>Key contributors to this growth included products like the Vyndaqel family, Comirnaty, and Paxlovid, alongside others such as Eliquis and Padcev.</li></ul>

Pfizer's Q2 2025 financial results reflect a blend of strategic execution and a challenging external milieu.The company reported revenues of $14.7 billion, marking a 10% operational increase year-over-year, driven by robust growth across the U.S. and international divisions.Key contributors to this growth included products like the Vyndaqel family, Comirnaty, and Paxlovid, alongside others such as Eliquis and Padcev.

Pfizer Inc.: Is Its $13 Billion M&A Budget & Product Pipeline Enough To Stay Ahead Of Rival Large Pharma?

<ul><li>Pfizer recently reported its first-quarter 2025 financial results, providing an overall positive snapshot of its performance within a challenging market environment.</li><li>Revenue was reported at $13.7 billion, marking a 6% operational decline largely driven by lower Paxlovid sales, partly reflecting a one-time Paxlovid revenue credit from the prior year.</li><li>Despite this, some of its core products such as the Vyndaqel family, Nurtec, and Padcev demonstrated strong growth, reinforcing the company’s focus on prioritizing key growth drivers.</li></ul>

Pfizer recently reported its first-quarter 2025 financial results, providing an overall positive snapshot of its performance within a challenging market environment.Revenue was reported at $13.7 billion, marking a 6% operational decline largely driven by lower Paxlovid sales, partly reflecting a one-time Paxlovid revenue credit from the prior year.Despite this, some of its core products such as the Vyndaqel family, Nurtec, and Padcev demonstrated strong growth, reinforcing the company’s focus on prioritizing key growth drivers.

Pfizer’s $15 Billion War Chest: What Will They Buy After the Danuglipron Failure?

United States

Pfizer Inc. operates as a pharmaceutical company. The Company offers medicines, vaccines, medical devices, and consumer healthcare products for oncology, inflammation, cardiovascular, and other therapeutic areas. Pfizer serves customers worldwide.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Pfizer (PFE UN)

Pfizer Secures a Major Regulatory Win—How Will Its U.S. Drug Pricing Deal Shape 2026?

The recent earnings call for Pfizer provides a detailed look at the company's financial and operational performance in the third quarter of...

Baptista Research

Pfizer and Novo Nordisk’s $10bn battle over weight-loss drugs

The battle between Pfizer and Novo Nordisk for biotech company Metcera highlights the fierce competition and high stakes in the lucrative weight...

Behind the Money

Pfizer's $4.9 Billion Metsera Bet: Can It Threaten Novo & Lilly’s Obesity Dominance?

Pfizer Inc has announced a definitive agreement to acquire clinical-stage biopharmaceutical company Metsera Inc. for $47.50 per share in cash, a...

Baptista Research

Pfizer Inc.: Is Its $13 Billion M&A Budget & Product Pipeline Enough To Stay Ahead Of Rival Large Pharma?

Pfizer's Q2 2025 financial results reflect a blend of strategic execution and a challenging external milieu. The company reported revenues of...

Baptista Research

Pfizer’s $15 Billion War Chest: What Will They Buy After the Danuglipron Failure?

Pfizer recently reported its first-quarter 2025 financial results, providing an overall positive snapshot of its performance within a challenging...

Baptista Research

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)